Using nanoparticles to improve treatment for tuberculosis and HIV
Official title: Immunotherapeutic nanoparticles: Implications for the treatment of tuberculosis and HIV
Funded at State University of New York at Buffalo · NIH-10897977 · Data updated 2026-11-12
This study is looking at a new way to help people with both tuberculosis and HIV by using tiny particles to deliver a medicine directly to their lungs, making it easier for their bodies to fight the infection while reducing side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project start | August 2, 2023 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $201,250 |
| NIH project number | 5R21AI179228-02 |
| Project ID | NIH-10897977 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who are at high risk of developing tuberculosis.
✕Less likely to help
Patients who do not have HIV or tuberculosis may not benefit from this research.
What this research studies
This research investigates a novel approach to treat tuberculosis (TB) in patients who are also living with HIV by using specially designed nanoparticles. These nanoparticles are engineered to deliver a drug called rifampin directly to immune cells in the lungs, enhancing the body's ability to fight off the infection. The study focuses on how effectively these nanoparticles can release the drug and stimulate the immune response over time. By targeting the delivery of medication, the goal is to reduce the side effects and improve the overall treatment regimen for these patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less burdensome treatment options for patients with both tuberculosis and HIV.
How similar studies have gone: While targeted drug delivery methods are being explored in various contexts, this specific approach using nanoparticles for TB and HIV treatment is relatively novel.
Where this research is happening
-
State University of New York at Buffalo
Amherst, United States Active
Researchers
- Principal investigator: Reynolds, Jessica L — State University of New York at Buffalo
- Study coordinator: Reynolds, Jessica L
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.